Terminal disclaimers sit at the crossroads of patent term and enforceability. They can save a patent during prosecution, yet trim years off its life and limit how you can enforce or transfer it. Used well, they solve a double‑patenting problem fast. Used reflexively, they can undercut portfolio value.
This guide explains what a terminal disclaimer is, when it helps, what it costs, and how recent cases reshape the calculus. You will get clear rules, practical tradeoffs, and steps you can put to work today.
TL;DR
- A terminal disclaimer cures nonstatutory double patenting by aligning the later patent’s term with an earlier patent and tying enforceability to common ownership.
- Filing a terminal disclaimer usually forfeits Patent Term Adjustment (PTA) on the later patent. Patent Term Extension (PTE) may still apply, as PTE compensates for delays unrelated to USPTO prosecution delays (such as FDA review).
- A terminal disclaimer filed under 37 C.F.R. §1.321 to obviate an obviousness-type double patenting rejection is not effective if the reference patent has already expired. In short, you generally must file the disclaimer while the reference patent is still in force; a retroactive disclaimer after expiration will not cure ODP.
- Portfolio value can drop because terminally disclaimed patents must remain commonly owned to be enforceable, complicating spin‑offs and asset sales.
- As of December 4, 2024, the USPTO withdrew its proposal to tighten terminal disclaimer enforcement, which would have introduced stricter conditions on how patents with terminal disclaimers could be enforced, particularly when ownership of related patents diverged. The current rules remain in place.
What a Terminal Disclaimer Is and Why It Exists
A terminal disclaimer (TD) is a written statement in which an applicant or patentee disclaims part of a patent term to overcome a judicially created double‑patenting problem. Double patenting has two flavors. Statutory double patenting bars two patents on the same invention.
Nonstatutory double patenting, often called obviousness‑type double patenting (ODP), bars a later patent whose claims are not patentably distinct from an earlier patent’s claims. The standard fix for ODP is a terminal disclaimer under 37 C.F.R. 1.321. The TD does two key things.
- First, it disclaims any term of the later patent that extends beyond the earlier patent’s term.
- Second, it conditions enforceability on common ownership with the reference patent (or, for joint research agreements, on not being separately enforced).
These conditions prevent time-wise extension of exclusivity and guard against harassment by multiple owners.
The Core Effects on Patent Term
Grasping how the 20-year baseline interacts with Patent Term Adjustment (PTA) and Patent Term Extension (PTE) is critical for calculating your actual window of exclusivity. This knowledge prevents costly surprises by highlighting how a Terminal Disclaimer can “cut off” valuable time gained through office delays.
- Twenty‑year baseline: For post‑URAA utility patents, the term is 20 years from the earliest effective non‑provisional filing date, subject to adjustments and extensions.
- Patent Term Adjustment (PTA): Compensates for USPTO delay. If you file a terminal disclaimer, PTA cannot extend the patent beyond the disclaimer date, and the Federal Circuit confirms that ODP is evaluated using the patent’s expiration after PTA is added.
- Patent Term Extension (PTE): Restores time lost to FDA review. A patent subject to a terminal disclaimer may still receive PTE. Courts have allowed PTE to extend beyond a disclaimed term because the PTE statute does not bar it the way PTA does.
Recent decisions reinforced these points. In re Cellect, the court held that ODP for a PTA‑adjusted patent is measured using the adjusted expiration. Patents that would only expire later due to PTA can be invalid for ODP unless properly disclaimed. Novartis v. Ezra and Merck v. Hi‑Tech confirm that PTE can extend a patent even with a terminal disclaimer, as the PTE statute does not have the same limitations as PTA.
Gilead v. Natco teaches that later‑expiring patents can be invalid over earlier‑expiring siblings even if the later‑expiring one issued first. Allergan v. MSN clarifies that a first‑filed, first‑issued patent in a family sets the maximum exclusivity and cannot be invalidated for ODP by later‑filed, later‑issued patents with a common priority date.
Enforcement, Ownership, and Irrevocability
By rule, a TD to overcome ODP must state the patent is enforceable only so long as it is commonly owned with the reference patent. If ownership splits later, enforceability stops until common ownership is restored. A TD filed under a joint research agreement waives separate enforcement, preventing multiple owners from suing independently.
Once a terminal disclaimer is recorded and the patent is granted, the commitment runs with the patent and binds successors and assigns. Withdrawal requests are not entertained after grant, except in rare cases, such as reexamination or other circumstances in which the USPTO may allow it. Also, you cannot cure ODP by filing a terminal disclaimer after the reference patent has already expired.
When a Terminal Disclaimer Makes Sense
This section helps you identify the specific scenarios where filing a TD provides a strategic advantage over fighting a rejection. It also serves as a warning system for high-stakes situations where a TD might accidentally destroy your portfolio’s monetization or spin-out potential.
A TD is appropriate when:
- The claims are not patentably distinct from a commonly owned earlier patent, and you want quick allowance.
- The family already has aligned terms, or the remaining term is not material to value.
- Maintaining common ownership is easy and expected for the life of the patents.
It is risky when:
- You depend on PTA to reach a critical exclusivity date.
- You plan to monetize by selling or spinning out assets, because enforceability hinges on keeping common ownership.
- The earlier patent is near or at expiration; once it expires, a TD cannot rescue ODP.
A Comparative Table of Patent Term Impact and Flexibility
This comparative overview empowers you to choose the path that best aligns with your business’s specific risk tolerance and revenue model.
| Option | What You Gain | What You Give Up | Best Used When |
| File Terminal Disclaimer | Fast path to allowance; clear ODP cure; portfolio peace | PTA beyond disclaimer date; enforceability tied to common ownership | Later patents’ extra term has low value; ownership will stay unified |
| Argue Patentable Distinctness | Keep full term (including PTA if any); preserve assignment flexibility | Longer prosecution; risk of appeal or continued ODP | Claims have real, supportable distinctions over reference claims |
| Use Section 121 Safe Harbor (Divisional) | Shield from ODP if restriction consonance is maintained | Needs proper divisional practice and claim grouping discipline | There was a restriction, and you stayed within the lines |
| Amend/Refocus Claims | Tailor scope to avoid ODP; keep term | Possible narrower coverage | You can focus on non‑obvious features without losing value |
Stay up to date with changes in patent law and ensure your portfolio remains compliant. Contact Goldstein Patent Law to discuss how this recent development affects your IP strategy.
Examples
Reviewing these real-world scenarios clarifies how abstract patent rules apply to concrete business transactions and helps you avoid common pitfalls that could lead to claim cancellation in litigation.
PTA at Risk in a Crowded Family
A company prosecuted a child application that picked up 400 days of PTA. The examiner issues an ODP rejection over a sibling with the same priority and a shorter term. If the company files a terminal disclaimer, the child will lose the PTA beyond the earlier patent’s expiration because a TD cannot extend a patent past the disclaimed date.
If it fights and loses, the claims could be canceled in reexamination or litigation under Cellect. The company weighs 400 days of exclusivity against the risk, cost, and time of appeal, then decides whether to narrow claims or disclaim.
Spin‑Out Collides With Common Ownership
A parent company holds two related patents; the latter one includes a terminal disclaimer tying enforceability to common ownership with the earlier patent. The business wants to spin out a product line and assign only the latter patent to the newco.
After the transfer, the later patent becomes unenforceable because common ownership with the reference patent has ended. The fix is to assign both patents, retain both, or structure a holding company so the same entity continues to own the linked assets.
Actionable Steps / Checklist
These steps provide a disciplined framework for protecting your most valuable terms and ensuring your patents remain enforceable throughout their entire lifecycle.
- Map your family early: List all related applications and patents, their priority chains, and projected expiration dates, including PTA and any potential PTE.
- Diagnose ODP exposure: Compare claim sets for patentable distinctness. Flag any later claims that track the earlier claim scope.
- Choose a path intentionally: If distinctions are real and supported, argue them. If not, consider amending or filing a TD. Use Section 121 safe harbor when you maintain restriction consonance in proper divisionals.
- Protect valuable term: Model revenue by month near expected expiry. If PTA drives meaningful value, avoid unnecessary TDs and consider narrowing amendments.
- Preserve enforceability: Keep commonly owned patents under one owner or holding company. For JRAs, ensure agreements and TD language satisfy non‑separate‑enforcement requirements.
- Mind timing: Do not wait to file a TD until after a reference patent expires; it will not cure ODP. Before issue, a mistakenly filed TD may be withdrawn by petition; after issue, it is effectively irrevocable.
- Track legal developments: Apply Cellect and Allergan rules when evaluating ODP and PTA. Note that the USPTO’s 2024 proposal to tighten TD enforceability was withdrawn on December 4, 2024.
Glossary
Understanding these foundational terms helps you navigate the complex interplay among USPTO delays, regulatory extensions, and double patenting rejections.
- Terminal Disclaimer (TD): A filing that disclaims part of a patent term and conditions enforceability to cure obviousness‑type double patenting.
- Obviousness‑Type Double Patenting (ODP): A doctrine that blocks a later patent with claims not patentably distinct from an earlier patent.
- Patent Term Adjustment (PTA): Extra term to offset USPTO delays; cannot extend beyond a disclaimer date.
- Patent Term Extension (PTE): Extra term for regulatory delay; can extend even if a terminal disclaimer exists.
- Common Ownership: Ownership by the same entity; required for enforceability of a TD‑linked patent.
- Joint Research Agreement (JRA): An agreement that can allow a TD when ownership differs, with a promise not to separately enforce.
- Restriction and Consonance: USPTO’s division of inventions into groups; keeping the same lines in later filings can trigger a safe harbor from ODP.
- Safe Harbor (35 U.S.C. 121): Protection from ODP for proper divisional applications that maintain restriction consonance.
FAQ
Q: Can I withdraw a terminal disclaimer later if I change strategy?
A: You generally cannot withdraw a recorded TD after grant; you may petition to withdraw prior to grant under 37 C.F.R. §1.182, but a TD recorded in an issued patent is typically irrevocable.
Q: Does a terminal disclaimer always kill PTA?
A: A terminal disclaimer prevents PTA from extending the patent past the disclaimer date. Courts also assess ODP using the PTA‑adjusted expiration, which can invalidate claims if no TD is in place.
Q: Can I use a terminal disclaimer to overcome prior art rejections?
A: You can’t use a terminal disclaimer to overcome prior art rejections. TDs address only nonstatutory double patenting, not prior art rejections under 35 U.S.C. 102 or 103.
Q: What happens if related TD‑linked patents end up with different owners?
A: When related TD-linked patents end up with different owners, the TD‑linked patent becomes unenforceable until common ownership is restored. For JRA TDs, separate enforcement is barred.
Q: Did the USPTO change terminal disclaimer rules in 2024?
A: The USPTO didn’t change terminal disclaimer rules in 2024. The May 10, 2024, proposal to add a new enforcement condition was withdrawn on December 4, 2024.
Final Thoughts
Terminal disclaimers are powerful but blunt. They can clear a path to allowance today by sacrificing tomorrow’s term and restricting the owner’s ability to transfer the patents separately. Treat them as a strategic tool, not a default. Model term value, preserve optionality where it matters, and document why each TD improves the portfolio rather than merely speeding prosecution.
Our patent lawyers are well-versed in handling the intricacies of terminal disclaimers and can guide you through the strategic decisions that affect your patent term, enforceability, and portfolio management. For expert legal guidance on how terminal disclaimers can impact your patent portfolio, contact Goldstein Patent Law today.
